Secretary of the CPC Hainan Provincial Committee Feng Fei Visits Dermavon Hainan

On August 10, 2026, Mr. Feng Fei, Secretary of the Hainan Provincial Committee of the Communist Party of China (CPC), headed a delegation for an inspection tour of Dermavon Hainan, a skin health subsidiary of China Medical System. The delegation conducted an on-site review of the company’s development, innovative R&D, and construction progress of Hainan R&D and Manufacturing Base. The inspection tour was accompanied by Fan Shaojun, Member of the Standing Committee of the Hainan Provincial Committee and Secretary of the Haikou Municipal Committee; Zhang Yong, Mayor of Haikou; Yang Zhongcheng, Director-general of the Policy Research Office of the Hainan Provincial Committee; Qi Shuli, Director of the Hainan Development and Reform Commission; Ji Tiejun, Director of the Hainan Medical Products Administration; Wang Yuan, Deputy Director-General of the Hainan Provincial Department of Industry and Information Technology.

During the inspection, Huang Anjun, Executive Director and CEO of Dermavon, gave a briefing to Secretary Feng and the accompanying delegation on the Company’s development strategy, innovative R&D layout, and the construction progress of its Hainan R&D and Manufacturing Base. Focusing on major skin diseases, Dermavon has developed a differentiated portfolio covering dermatological prescription products and dermatology-grade skincare products, while continuing to enhance its integrated capacities covering R&D, manufacturing and commercialization. The main structure of the Hainan R&D and Manufacturing Base will soon be topped out. Going forward, Dermavon will capitalize on the strengths of the biopharmaceutical pillar industry of the Hainan Free Trade Port to further enhance its capacity for industrializing innovative products.

During the discussion, Huang Anjun introduced Dermavon’s innovative drug Ruxolitinib Phosphate Cream (Lumirix®), in-licensed from Incyte, as a successful outcome of the “Lecheng R&D and Clinical Use + Haikou Manufacturing” model. Government authorities at all levels in Hainan provided efficient guidance and strong support throughout the advancement of the product, laying a solid foundation for its accelerated launch on the domestic market, and establishing a complete Hainan-based pathway to introduce global innovative medicines into China.

Secretary Feng affirmed Dermavon’s business model centered on skin health and innovation. He encouraged the company to further leverage the advantages of the healthcare industry at the Hainan Free Trade Port, deepen synergy between the innovation and industrial chains, grow together with regional industry partners, and bring more high-quality innovative products to patients.

The visit shows the recognition of Dermavon’s innovation development achievements and highlights Hainan’s strong commitment to innovation and the translation of scientific and technological achievements in the biopharmaceutical sector. Dermavon will continue to advance the high-standard, efficient construction of its Hainan R&D and Manufacturing Base, increase investment in R&D and talent recruitment, and speed up the industrial translation of innovative products. By converting the Hainan Free Trade Port’s policy dividends into its driving forces for industrial development, Dermavon will continue contributing to the expansion of Hainan’s biopharmaceutical industrial cluster and the upgrading of the Free Trade Port’s healthcare industry.

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.